




# Q2 2024 Financial Results



Total Revenues  
**\$3.80B**

Adjusted EBITDA\*  
**\$1.21B**

Free Cash Flow<sup>1\*</sup>  
Excluding Transaction Costs  
**\$426M**

Adjusted EPS\*  
**\$0.69**

Expects 2024 Full-Year Operational Revenue Growth of ~2%<sup>2\*</sup>



"I am pleased to report strong second quarter results in which we delivered divestiture-adjusted operational revenue growth across all segments, including strong growth in Greater China. This represents our fifth consecutive quarter of divestiture-adjusted operational revenue growth and demonstrates our ability to execute and grow our base business. With our divestitures behind us and a strong foundation to build on, we believe we are at an inflection point for our Company. In our next chapter, our strategy will focus on three main pillars: our diversified and growing base business, our financial strength and significant cash flow, and our expanding innovative portfolio. We expect these three pillars will enable us to accelerate growth and shareholder return."

– Scott A. Smith  
Chief Executive Officer

## Three Strategic Pillars to Accelerate Growth and Shareholder Return

 <p><b>DIVERSIFIED &amp; GROWING BASE BUSINESS</b></p>	 <p><b>FINANCIAL STRENGTH &amp; SIGNIFICANT CASH FLOW</b></p>	 <p><b>EXPANDING INNOVATIVE PORTFOLIO</b></p>
<p>An extensive global footprint that reaches ~1 billion patients annually<sup>3</sup></p> <p>A large and diversified portfolio of generics and off-patent brands across markets and therapeutic areas</p>	<p>Strong balance sheet and cash flow generation</p> <p>Commitment to debt reduction and returning capital to shareholders through dividends and share repurchases</p>	<p>Patent-protected assets that have the potential for meaningful revenue growth and patient impact</p> <p>Disciplined investments in innovative assets that have a validated mechanism of action, strong clinical proof of concept and a clear path to regulatory approval</p>

## Building Sustainable Access at Scale

Supplying high-quality medicines to  
**~1 billion**  
patients around the world annually<sup>3</sup>



Viatriis named to **TIME's World's Most Sustainable Companies 2024 List** which recognizes leading companies in corporate social responsibility from over 30 countries.



Viatriis named to **USA TODAY's list of America's Climate Leaders** for companies that have demonstrated the greatest reduction in emissions intensity

<sup>1</sup>Non-GAAP Financial Measure. For more information about Non-GAAP financial measures and reconciliations to the closest U.S. GAAP financial measure, as well as risks related to forward-looking statements, please read our [2Q 2024 financial results press release](#) on our website.  
<sup>2</sup>Non-GAAP Financial Measure. Q2 2024 Free Cash Flow was \$320M. Q2 2024 Free cash flow, excluding the impact of transaction costs related to the divestitures of \$106M, was \$426M.  
<sup>3</sup>Expecting 2024 full-year total revenue growth of 2% on a divestiture-adjusted operational basis. U.S. GAAP Total Revenues for 2024 as of August 8, 2024 is estimated to be between \$14,600M and \$15,100M, with a midpoint of approximately \$14,850M or a full year decrease of 4%.  
<sup>4</sup>See our 2023 Sustainability Report page 4 for more information.



[Viatriis.com](#)



[LinkedIn](#)



[@ViatriisInc](#)



[@ViatriisInc](#)



[YouTube](#)



[Listen Well Podcast](#)